ADH5 and asthma: These studies showed that inhibition of GSNOR activity with a single intravenous (i.v.)dose of N6022 imparted potent effects against key parameters in asthma, specifically, AHR and eosinophilic inflammation, with mechanisms consistent with restoring normal levels and function of SNOs in the airways.